The University of Kansas Cancer Center

https://www.kucancercenter.org/

 

KU ASCO 2019 Hairy Cell Leukemia Highlights - Moxetumomab Pasudotox for Relapsed/Refractory Disease & Concurrent Rituximab with Cladribine for 1st Line

60 views
August 2, 2019
Comments 0
Login to view comments. Click here to Login